Celentyx Ltd is a CRO offering bespoke assay services in human immunology, including immuno-oncology, autoimmunity & inflammation, fibrosis and neuroinflammation.
Celentyx’s unique ImmuKnowlogy™ platform allows rapid analysis of drug action on human immune cells – from healthy donors or patients with defined clinical disease. Drawing on the World-leading expertise of Celentyx personnel, which along with our strategic relationships with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research (at the Queen Elizabeth ‘Super-hospital’, Birmingham), enables the human immune system to be investigated at the highest levels of resolution. Celentyx’s ImmuKnowlogy™ services enable partners to quantify efficacy, elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man. Celentyx’s Novel Clinical Indication Profiling™, which applies the powerful Immuno-Profiling™ platform to reprofile (repurpose) drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug indications.
Celentyx Ltd’s Immunology Assay Services offer a suite of tools and expertise to dissect the precise action of drugs on healthy donor or patient immune cells, including action on critical rare subsets. With more than a decade of experience in successful assay development, Celentyx is often called upon to develop bespoke assays to meet specific client needs.